We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants.

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

The update was delivered at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February ...

Iovance Biotherapeutics, Inc. IOVA incurred a fourth-quarter 2024 loss of 26 cents per share, narrower than the Zacks ...

Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIR ...

Berenberg analyst Luisa Hector lowered the firm’s price target on Merck (MRK) to $115 from $125 and keeps a Buy rating on the shares. Merck ...

LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and ...

FDA recently announced new safety requirements for DPD screening in cancer patients. Kristine Ashcraft, founder and CEO of ...

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...